In Specialty Pharma, First Horizon's Low Cost Sales Model
In 2003, after a string of bad luck that had sent its stock down 81%, First Horizon overhauled its management team and began to implement a new low-cost sales strategy. It appears to be working. First quarter 2004 income was $8.2 million, compared to a loss of almost $14 million a year ago. Prescriptions of its key product, calcium channel blocker nisoldipine (Sular), were up 10% in the quarter, and this was evidently enough to convince pharmaceutical company SkyePharma PLC to grant the specialty pharma US marketing rights to an unnamed cardiovascular product.
You may also be interested in...
The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.